Premium
Consequences of chronic hepatitis C: A review article for the hematologist
Author(s) -
Aledort Louis M.
Publication year - 1993
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.2830440107
Subject(s) - medicine , hepatitis c virus , immunology , interferon alfa , virology , chronic hepatitis , interferon , hepatitis c , recombinant dna , antibody , bdna test , hepatitis , alpha interferon , virus , biology , biochemistry , gene
The hepatitis C virus (HCV) has been cloned, and assays capable of detecting antibody to HCV recombinant proteins (anti‐HCV) have been developed. Concurrent with the cloning and development of the anti‐HCV screening tests, trials with interferon alfa‐2b have documented biochemical and histologic improvement in the indices of hepatitis C and non‐A, non‐B (NANB) in patients who were chronically infected. Subsequently, the anti‐HCV assays and interferon alfa‐2b have become clinically available. These new detection and treatment modalities can now be used in the management of hemophilics and other chronically transfused patients who bear great risk for blood‐borne infections and manifest signs of chronic hepatitis. © 1993 Wiley‐Liss, Inc.